Indian court blocks Glenmark's Januvia generic but it ain't over yet
This article was originally published in Scrip
Executive Summary
An Indian court has granted an interim injunction against Glenmark in the high profile case concerning the patent infringement of Merck & Co's diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride).